Samsung Bioepis’ biosimilar adalimumab, SB5, has been approved in the European Union under the name Imraldi on the basis of clinical studies including a phase 3 study in patients with rheumatoid arthritis. Now that the biosimilar has begun to make its way to EU patients, investigators are publishing new data on other key facets of the product, including its shelf life and device usability.
Samsung Bioepis’ biosimilar adalimumab, SB5, has been approved in the European Union under the name Imraldi on the basis of clinical studies including a phase 3 study in patients with rheumatoid arthritis (RA). Now that the biosimilar has begun to make its way to EU patients, investigators are publishing new data on other key facets of the product, including its shelf life and device usability.
In a paper newly published in Advances in Therapy1, investigators explained that SB5 is currently approved for storage between 2 to 8 degrees Celsius for 36 months, and may be stored at room temperature for a maximum of 14 days. In their study, the investigators sought to evaluate whether SB5, aged to its full shelf life of 36 months, could then be stored at room temperature for a period of 4 weeks. These conditions, they say, represent a worst-case scenario for medication storage in circumstances in which patients face long period without continuous access to refrigeration.
The investigators used 3 different batches of 36-month aged SB5 and stored them at room temperature for 4 weeks. They tested the samples at baseline and again at week 2 and 4.
According to the investigators, the color and clarity of the drug did not change over time, nor did the presence of visible particles. The pH of the product also remained stable for the 4-week period.
High—molecular weight impurities did not increase, the total purity of SB5 remained at or above 95.0%, and the degree of nonglycosylation of heavy antibody chains remained below 4.3% for 4 weeks, indicating that there was no degradation of the monoclonal antibodies. SB5’s biological activity remained stable over the 4-week period, as measured by competitive inhibition binding and TNF-alpha neutralization assays.
The paper’s authors conclude that SB5 remained stable and biologically active for 4 weeks at room temperature after aging to its shelf life, suggesting that the stability profile is 2 weeks longer than is currently approved in the European Union.
A separate investigation, published in Current Medical Research and Opinion2, sought to investigate a question that is key to patients who are being switched to a biosimilar: injection site pain and safety of injection with either a prefilled syringe or an autoinjector pen.
In the open-label study in 49 patients with RA, patients self-administered their 40-mg doses of adalimumab subcutaneously with a syringe at weeks 0 and 2 of the study, followed by an autoinjector at weeks 4 through 10. Patients rated their injection site pain from 0 (no pain) to 10 (severe pain) at weeks 0, 2, 4, and 6.
Mean injection site pain scores were equivalent between the prefilled syringe and autoinjector immediately after the injection (2.3 versus 2.0; 97.5% CI, −0.99-0.30) and 15 to 30 minutes after the injection (0.8 versus 0.7; 97.5% CI, −0.47-0.25). Patients reported that their overall impression of both devices was comparable, through their overall preference was for the autoinjector. Treatment-emergent adverse events (AEs) were all mild to moderate, and there were no serious AEs reported.
Overall, wrote the investigators, SB5 showed equivalent injection site pain and comparable safety when administered by either of the 2 injection devices.
Reference
1. Park D, Yun J, Hwang SJ, Park SJ. Evaluation of physicohemical and biological stability of 36-months-aged SB5 (adalimumab biosimilar) for 4 weeks at room temperature [published online December 15, 2018]. Adv Ther. doi: 10.1007/s12325-018-0851-5.
2. Ghil J, Zielinska A, Lee Y. Usability and safety of SB5 (an adalimumab biosimilar) prefilled syringe and autoinjector in patients with rheumatoid arthritis [published online December 18, 2018]. Curr Med Res Opin. doi: 10.1080/03007995.2018.1560211.
Sandoz Report: A Unified Approach to Overcoming Drug Shortages
October 10th 2024A report from Sandoz emphasizes the need for collaboration among stakeholders to eliminate drug shortages impacting over 90% of hospital systems in the US, recommending policy changes and actions to address the ongoing issue, which has caused treatment delays and increased costs.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
AAM Report: Despite Massive Savings, Patient OOP Costs on Biosimilars, Generics Remain High, Part 2
September 24th 2024Part 2 of our series diving into the Association for Accessible Medicines' (AAM) latest report discusses that while generics and biosimilars saved $445 billion in 2023, their potential is hindered by high patient costs, drug shortages, and ineffective policies, underscoring the need for reforms to fully realize their benefits.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
Expanding Biosimilar Adoption: Insights and Strategies With Dr Sophia Humphreys
September 16th 2024Sophia Humphreys, PharmD, MHA, BCBBS, director of system formulary management at Sutter Health, discusses the challenges of expanding biosimilars into new therapeutic areas and highlights the role of education, competitive pricing, and integrated delivery networks in improving adoption and market growth.
Real-World Study Shows Comparable Outcomes Between CT-P13, Remicade in RA
September 14th 2024A real-world study of the biosimilar infliximab-dyyb (CT-P13; Inflectra) in rheumatoid arthritis (RA) reported the majority of patients who initiated CT-P13 switched from the reference product (Remicade) or another biologic or targeted synthetic disease-modifying antirheumatic drug.